Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models [Yahoo! Finance]
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program [Yahoo! Finance]
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing [Yahoo! Finance]